CN101103967B - Medicine composition containing bevantolol hydrochloride - Google Patents
Medicine composition containing bevantolol hydrochloride Download PDFInfo
- Publication number
- CN101103967B CN101103967B CN2006100365434A CN200610036543A CN101103967B CN 101103967 B CN101103967 B CN 101103967B CN 2006100365434 A CN2006100365434 A CN 2006100365434A CN 200610036543 A CN200610036543 A CN 200610036543A CN 101103967 B CN101103967 B CN 101103967B
- Authority
- CN
- China
- Prior art keywords
- bevantolol hydrochloride
- bevantolol
- microcrystalline cellulose
- magnesium stearate
- hydrogen phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003588 bevantolol Drugs 0.000 title claims abstract description 37
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000008187 granular material Substances 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 16
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000007605 air drying Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000007787 solid Substances 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229960002237 metoprolol Drugs 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- DKTVQFUMIUPSGI-UHFFFAOYSA-N 1-(3-methylphenoxy)propan-2-ol Chemical compound CC(O)COC1=CC=CC(C)=C1 DKTVQFUMIUPSGI-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a drug compound containing bevantolol hydrochloride and the preparation method. The drug compound exists in the form of powder or a granule, applied after tablet forming or arrangement in a capsule. The preparation process is simple and applicable for commercial production.
Description
Technical field
The present invention relates to a kind of treatment hypertension, anginal medicine, special is the pharmaceutical composition of active substance with the bevantolol.
Technical background
Hypertension has become the main killer of harm humans health in recent years.China has 1.2 hundred million people to suffer from hypertension approximately according to statistics.Bevantolol is the selective ' beta '3 adrenergic beta-blocker of new generation by the exploitation of U.S. Warner-Lambert company, have the depressor of the vasorelaxation action of α 1 receptor retardance concurrently, the bioavailability 60% of bevantolol, peak time 2 hours, plasma half-life 1.5 hours, its metabolite 4-hydroxyl bevantolol has antihypertensive active.Bevantolol selectivity β 1 blockage effect is close with metoprolol, and α 1 receptor retardation slightly is weaker than labetalol, and does not have the effect of endogenous sympathetic stimulation.Bevantolol is compared with metoprolol, and the amplitude that the latter slows down is greater than the former, and bevantolol has better toleration than metoprolol.Retardance α that can be parallel and beta receptor bring high blood pressure down and can offset mutual adverse effect, reach the effect of drug combination.
The bevantolol chemical name is 1-[[2-(3, the 4-Dimethoxyphenyl)-ethyl]-amino]-3 (3-methylphenoxy)-2-propanol, structural formula is:
The invention provides the pharmaceutical composition of the bevantolol of quick acting and determined curative effect, said composition can further be prepared into the pharmaceutical preparation of oral solid formulation category.This pharmaceutical composition exists with powder or particulate form, can be with powder or the granule tabletting or the application of encapsulated back of this pharmaceutical composition, and without coating, preparation technology is simple, is fit to suitability for industrialized production, and good stability.
Summary of the invention
The invention provides a kind of combination of oral medication, this pharmaceutical composition is that powder or particulate form exist, can be with powder or the granule tabletting or the application of encapsulated back of this pharmaceutical composition, and preparation technology is simple, is fit to suitability for industrialized production.Selected other pharmaceutically suitable carrier are common medicinal supplementary material, have no side effect and obvious irritation.
The invention provides a kind of pharmaceutical composition that contains bevantolol, the percentage by weight that contains bevantolol is 10%-70%, preferred 20%-50%.
The invention provides a kind of pharmaceutical composition that contains bevantolol, contain percentage by weight 5%-70%, the calcium hydrogen phosphate of preferred 10%-50%, the pharmaceutical composition behind the adding calcium hydrogen phosphate has good mobility, and this can improve principal agent and stability of formulation as inert excipients.
The invention provides a kind of pharmaceutical composition that contains bevantolol, also contain percentage by weight 5%-70%, the microcrystalline Cellulose of preferred 10%-50% has guaranteed that preparation of compositions has good disintegrating property, flowability or compressibility when becoming solid preparation.Microcrystalline Cellulose can be selected from microcrystalline cellulose PH101, PH102, PH301, PH302 etc., and processes such as fill when making preparation of compositions become preparation, filling or tabletting are smooth.
The invention provides a kind of pharmaceutical composition that contains bevantolol, contain percentage by weight 0%-50%, the starch of preferred 5%-25% has guaranteed the molding of the solid preparation that preparation of compositions becomes and has had good disintegrating property.Starch can be selected from potato starch, wheaten starch, corn starch, pregelatinized Starch.
The invention provides a kind of pharmaceutical composition that contains bevantolol, contain percentage by weight 0%-20%, the disintegrating agent of preferred 5%-15% has guaranteed the good disintegrating property that has of solid preparation that preparation of compositions becomes.The optional self-crosslinking polyvidone of disintegrating agent, cross-linked carboxymethyl cellulose sodium, carboxymethylstach sodium or low-substituted hydroxypropyl cellulose, particularly preferred is polyvinylpolypyrrolidone, comprises
XL,
XL-10,
INF-10.
The invention provides a kind of pharmaceutical composition that contains bevantolol, contain percentage by weight 5%-70%, the starch of preferred 10%-50% has guaranteed that the solid preparation that preparation of compositions becomes has good disintegrating property.Starch can be selected from potato starch, wheaten starch, corn starch, pregelatinized Starch.
In order to finish the present invention, fill when making preparation of compositions become preparation, filling or tabletting process are smooth, need in the compositions to add the moderate lubrication agent, and that can mention especially has:
Magnesium stearate, calcium stearate or aluminium stearate;
Has molecular weight and is 4000 to 8000 Polyethylene Glycol (PEG);
Oleum Brassicae campestris, palmitoleoyl tristerin, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, magnesium laurylsulfate.
Most preferred lubricant comprises magnesium stearate, calcium stearate or aluminium stearate.
Added percentage by weight 0.2%-1.5% in this compositions, the magnesium stearate of preferred 0.5%-1% is as lubricant.
Pharmaceutical composition provided by the present invention exists with powder or particulate form, it is characterized in that powder or granule tabletting or the application of encapsulated back with this pharmaceutical composition.
Adopt the pharmaceutical preparation that is used for slight or moderate hypertension, anginal oral solid formulation category of aforementioned pharmaceutical compositions preparation, have the following advantages: stripping is rapid, the dissolution height, and good stability, preparation technology is simple, is easy to realize suitability for industrialized production.
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment, but be not limited to following embodiment.Wherein " % " is meant " weight % ".
Embodiment 1
Preparation technology:
Bevantolol hydrochloride is crossed 100 mesh sieves, microcrystalline Cellulose PH101, calcium hydrogen phosphate, starch, polyvinylpolypyrrolidone-XL, magnesium stearate are crossed 60 mesh sieves respectively, take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH101, calcium hydrogen phosphate, starch, polyvinylpolypyrrolidone-XL (in add part) and mix, with water is wetting agent system soft material, crossing 18 mesh sieves granulates, 60 ℃ of forced air dryings, with 24 mesh sieve granulate, add polyvinylpolypyrrolidone-XL (Extra Section), magnesium stearate, mix homogeneously is with the stamping of Ф 9mm scrobicula.
Embodiment 2
Preparation technology:
Bevantolol hydrochloride is crossed 100 mesh sieves, and microcrystalline Cellulose PH101, calcium hydrogen phosphate, magnesium stearate are crossed 60 mesh sieves respectively, and be standby.Take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH101, calcium hydrogen phosphate and mixing, add wetting agent water system soft material, cross 30 mesh sieves and granulate, 60 ℃ of forced air dryings with 30 mesh sieve granulate, add magnesium stearate, mix homogeneously, No. 2 capsules of fill capsule.
Embodiment 3
Preparation technology:
Bevantolol hydrochloride is crossed 100 mesh sieves, microcrystalline Cellulose PH102, calcium hydrogen phosphate, starch, cross-linked carboxymethyl cellulose sodium, magnesium stearate are crossed 60 mesh sieves respectively, take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH102, calcium hydrogen phosphate, starch, cross-linked carboxymethyl cellulose sodium and mixing, with water is wetting agent system soft material, crosses 18 mesh sieves and granulates, 60 ℃ of forced air dryings, with 24 mesh sieve granulate, add magnesium stearate, mix homogeneously is with the stamping of Ф 8mm scrobicula.
Embodiment 4
Preparation technology:
Bevantolol hydrochloride is crossed 100 mesh sieves, microcrystalline Cellulose PH101, calcium hydrogen phosphate, starch, carboxymethylstach sodium, magnesium stearate are crossed 60 mesh sieves respectively, take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH101, calcium hydrogen phosphate, starch, carboxymethylstach sodium and mixing, with water is wetting agent system soft material, crosses 18 mesh sieves and granulates, 60 ℃ of forced air dryings, with 24 mesh sieve granulate, add magnesium stearate, mix homogeneously is with the stamping of Ф 7mm scrobicula.
Embodiment 5
Preparation technology:
Bevantolol hydrochloride is crossed 100 mesh sieves, and microcrystalline Cellulose PH101, calcium hydrogen phosphate, polyvinylpolypyrrolidone XL, magnesium stearate are crossed 60 mesh sieves respectively, and be standby.Take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH101, calcium hydrogen phosphate, polyvinylpolypyrrolidone XL and mixing, add wetting agent water system soft material, cross 30 mesh sieves and granulate, 60 ℃ of forced air dryings with 30 mesh sieve granulate, add magnesium stearate, mix homogeneously, No. 3 capsules of fill capsule.
The dissolution test
Pressing dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2000), is dissolution medium with water 900ml, and rotating speed is 50 rev/mins.Measure dissolution at 276nm wavelength place according to ultraviolet spectrophotometry (two appendix IVA of Chinese Pharmacopoeia version in 2000).Measure the dissolution of comparison film (bevantolol hydrochloride sheet, 0114, Nippon Chemiphar Co., Ltd.) with method, the results are shown in following table.
Table 1 each embodiment prescription and comparison film dissolution result
Stability test
The various embodiments described above sample, simulation listing packing is to carry out accelerated test under 75% ± 5% (NaCl saturated solution) condition in 40 ℃ ± 2 ℃, relative humidity, by the sampling of fixing the date, the inspection gainer, result of the test sees Table 2.
Each embodiment accelerated test result of table 2 (40 ℃ ± 2 ℃, 75% ± 5%RH)
As can be seen from the above table, according to the pharmaceutical preparation that is used for slight or moderate hypertension, anginal oral solid formulation category of preparation of pharmaceutical compositions of the present invention, have the following advantages: stripping is rapid, the dissolution height, good stability, preparation technology is simple, is easy to realize suitability for industrialized production.
Claims (3)
1. the pharmaceutical composition of a bevantolol hydrochloride is characterized in that being made up of following composition and percentage by weight: 22.7% bevantolol hydrochloride, 36.4% microcrystalline Cellulose PH101,39.9% calcium hydrogen phosphate and 1.00% magnesium stearate.
2. bevantolol hydrochloride preparation of drug combination technology according to claim 1, be specially: bevantolol hydrochloride is crossed 100 mesh sieves, and microcrystalline Cellulose PH101, calcium hydrogen phosphate, magnesium stearate are crossed 60 mesh sieves respectively, and be standby; Take by weighing recipe quantity bevantolol hydrochloride, microcrystalline Cellulose PH101, calcium hydrogen phosphate and mixing, add wetting agent water system soft material, cross 30 mesh sieves and granulate, 60 ℃ of forced air dryings with 30 mesh sieve granulate, add magnesium stearate, mix homogeneously, No. 2 capsules of fill capsule.
3. the pharmaceutical composition of a bevantolol hydrochloride is characterized in that being made up of following composition and percentage by weight: 16.13% bevantolol hydrochloride, 48.39% microcrystalline Cellulose PH101,12.90% calcium hydrogen phosphate, 15.48% starch, 6.45% polyvinylpolypyrrolidone-XL and 0.65% magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100365434A CN101103967B (en) | 2006-07-14 | 2006-07-14 | Medicine composition containing bevantolol hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100365434A CN101103967B (en) | 2006-07-14 | 2006-07-14 | Medicine composition containing bevantolol hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101103967A CN101103967A (en) | 2008-01-16 |
| CN101103967B true CN101103967B (en) | 2011-01-19 |
Family
ID=38998181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100365434A Active CN101103967B (en) | 2006-07-14 | 2006-07-14 | Medicine composition containing bevantolol hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101103967B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579329B (en) * | 2009-06-08 | 2011-11-09 | 沈阳亿灵医药科技有限公司 | Bevantolol hydrochloride sustained release preparation |
| CN104138360B (en) * | 2013-05-06 | 2016-03-02 | 扬子江药业集团上海海尼药业有限公司 | The preparation method of bevantolol hydrochloride sheet |
-
2006
- 2006-07-14 CN CN2006100365434A patent/CN101103967B/en active Active
Non-Patent Citations (5)
| Title |
|---|
| JP 52-234 A,全文. |
| 罗明生等.药剂辅料大全 1.四川科学技术出版社,1993,419、643、664、665、715、742、852. |
| 罗明生等.药剂辅料大全 1.四川科学技术出版社,1993,419、643、664、665、715、742、852. * |
| 陈素俭等.盐酸贝凡洛尔片溶出度测定方法的研究.中国药品标准2 4.2001,2(4),60-62. |
| 陈素俭等.盐酸贝凡洛尔片溶出度测定方法的研究.中国药品标准2 4.2001,2(4),60-62. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101103967A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10064826B2 (en) | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process | |
| JPH10194969A (en) | Tablet composition | |
| JP5610865B2 (en) | Solid preparation | |
| SK6472000A3 (en) | Spheroid core, spheroid with its content, pharmaceutical composition comprising them and method for their producing | |
| US20030013740A1 (en) | Stable dosage forms of fluoxetine and its enantiomers | |
| AU2010274589A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
| EP2197428B1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| CN106309403A (en) | Pharmaceutical composition containing lenalidomide, and preparation method and medical application thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN101721410A (en) | Solid medicinal composition of clopidogrel hydrogen sulfate | |
| JP2005314413A (en) | Medicine composition for oral administration | |
| US20150141520A1 (en) | Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof | |
| PL236001B1 (en) | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, | |
| JP7104039B2 (en) | Pharmaceutical composition | |
| CN101103967B (en) | Medicine composition containing bevantolol hydrochloride | |
| CN103417501B (en) | Pharmaceutical composition of topiramate | |
| CN101991561A (en) | 3,4-dichlorophenyl-propenoyl-sec-butylamine composition | |
| CN109464442B (en) | Sacubitril valsartan sodium pharmaceutical composition and preparation method thereof | |
| CN111773191A (en) | Compound solid preparation containing phenylephrine hydrochloride and preparation method thereof | |
| CN102068415B (en) | Carbazole sulfonamide anti-tumor medicine dispersible tablets and preparation method thereof | |
| TWI468189B (en) | Oral internal disintegrating tablet and its manufacturing method | |
| KR101175816B1 (en) | Sustained release tablet for oral use | |
| JP2019089758A (en) | Method for improving dissolution in celecoxib-containing tablets | |
| KR101910707B1 (en) | Metformin Extended-release Tablets Having Enhanced Patient Compliance and its Preparing Method | |
| Reshma et al. | Superdisintegrants and their inevitable role i n orodispersible tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SIHUANKEBAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HAINAN SHENGKE LIFE SCIENTIFIC RESEARCH INSTITUTE Effective date: 20140623 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570311 HAIKOU, HAINAN PROVINCE TO: 100070 FENGTAI, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140623 Address after: 100070 Beijing science and Technology Park of Fengtai Haiying Road No. 11 Patentee after: Beijing Sihuankebao Pharmaceutical Co., Ltd. Address before: 570311 No. 175 Binhai Avenue, Hainan, Haikou Patentee before: Hainan Shengke Life Scientific Research Institute |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 102629 No. 5, Xiangrui street, biomedical base, Daxing District, Beijing Patentee after: Beijing Sihuan Kebao Pharmaceutical Co.,Ltd. Address before: 100070 Beijing science and Technology Park of Fengtai Haiying Road No. 11 Patentee before: BEIJING SIHUAN KEBAO PHARMACEUTICAL Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Wang Liqin Document name: Notification of qualified procedures |
|
| DD01 | Delivery of document by public notice |